Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097492 - TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS

Publication Number WO/2020/097492
Publication Date 14.05.2020
International Application No. PCT/US2019/060516
International Filing Date 08.11.2019
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
G01N 33/48 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Applicants
  • THE BROAD INSTITUTE, INC. [US]/[US]
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
Inventors
  • CORSELLO, Steven
  • SPANGLER, Ryan
  • NAGARI, Rohith
  • GOLUB, Todd
Agents
  • COWLES, Christopher R.
  • JOBSE, Bruce, D.
  • SERIO, John, C.
  • COHEN, Jerry
  • GOLDMAN, Gabriel
  • GOMES, David, W.
  • HAASAN, Shahid
  • LOPEZ, Orlando
  • MARAIA, Joseph
  • MILLS, Stephen
  • MOORE, Ronda
  • QUINN, Joseph, P.
  • SCHEPPER, Marlo
  • SORKIN, Paul
  • SUSAN, Janine
  • MCGRATH, Daniel
  • CHACLAS, George
  • EMMONS, Richard
  • FOLEY, Shawn
  • KARIMI, Pegah
  • DUBEROW, Eilene
Priority Data
62/758,29409.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS
(FR) CIBLAGE DE TÉPOXALINE POUR CANCERS SUREXPRIMANT ABCB1
Abstract
(EN)
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers that exhibit elevated expression and/or amplification of the ABCB1 (MDR1) transporter, optionally for reasons related to development of chemotherapeutic resistance having occurred during treatment with an initial chemotherapeutic drug. In particular, the instant disclosure provides for identification of a cancer as possessing elevated ABCB1 expression and/or exhibiting resistance to a non-tepoxalin chemotherapeutic drug, and selecting and/or administering tepoxalin, a tepoxalin derivative and/or metabolite thereof as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer. Methods and compositions for therapies that combine such tepoxalin or tepoxalin-related compounds with other cancer therapies and/or chemotherapeutic agents are also provided.
(FR)
La présente invention concerne des compositions et des procédés pour le diagnostic et le traitement ou la prévention de cancers qui présentent une expression et/ou une amplification élevées du transporteur ABCB1 (MDR1), éventuellement pour des raisons liées au développement d'une résistance chimiothérapeutique ayant eu lieu pendant le traitement avec un médicament chimiothérapeutique initial. En particulier, la présente invention concerne l'identification d'un cancer comme possédant une expression d'ABCB1 élevée et/ou présentant une résistance à un médicament chimiothérapeutique sans tépoxaline, et la sélection et/ou l'administration de tépoxaline, d'un dérivé de tépoxaline et/ou d'un métabolite associé en tant qu'agent thérapeutique pour un tel cancer et/ou sujet ayant ou risquant de développer un tel cancer. La présente invention concerne également des procédés et des compositions pour des thérapies qui combinent ladite tépoxaline ou des composés apparentés à la tépoxaline avec d'autres thérapies anticancéreuses et/ou agents chimiothérapeutiques.
Latest bibliographic data on file with the International Bureau